Table 1.
Genotype and therapeutic response
| Baseline Frequency | Association between SNPs and pCR | ||||||
|---|---|---|---|---|---|---|---|
| SNP | Geno-type | No. (%) | Variant allele groupa vs major homozygote | No pCR/pCR (No.) | OR | 95% CI | p |
| XRCC1 Arg399Gln (rs25487) | AA | 12 (20) | |||||
| AG | 19 (32) | AA or AG | 29/2 | ||||
| GG | 29 (48) | GG | 21/8 | 5.37 | 0.94-57.0 | 0.062 | |
| XRCC2 5' flank (rs6464268) | GG | 1 (2) | |||||
| GA | 16 (27) | GG or GA | 13/4 | ||||
| AA | 43 (72) | AA | 37/6 | 0.53 | 0.11-2.99 | 0.59 | |
| ERCC1 3' flank (rs3212986) | TT | 0 | |||||
| GT | 22 (37) | GT | 17/5 | ||||
| GG | 38 (63) | GG | 33/5 | 0.52 | 0.10-2.60 | 0.54 | |
| XPD Lys751Gln (rs13181) | GG | 8 (13) | |||||
| GT | 29 (48) | GG or GT | 30/7 | ||||
| TT | 23 (38) | TT | 20/3 | 0.64 | 0.10-3.3 | 0.83 | |
| XPD Asp312Asn (rs1799793) | AA | 7 (12) | |||||
| AG | 28 (47) | AA or AG | 28/7 | ||||
| GG | 25 (42) | GG | 22/3 | 0.55 | 0.082-2.77 | 0.65 | |
CI, confidence interval; OR, odds ratio for non-pCR of variant allele group as compared to the major homozygote; pCR, complete pathologic response; SNP, single nucleotide polymorphism.
a The variant allele group consists of the variant allele homozygote and heterozygote in combination.